A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
Active, not recruiting · Phase 1 · NCT06318273
Conditions: Metastatic Castration-Resistant Prostate Cancer
At a glance
- Research payments reported, 2025
- $3.4M
- U.S. investigators named
- 9
- Sites paid
- 15
- Planned or actual enrollment
- 152
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-969 (drug)
- Dates
- Started 2024-03-08; completion 2027-05
- Results posted
- Not yet
Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy. ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 230 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-969 will be intravenously infused in escalating doses as a monotherapy. In part 2, multiple doses w…
From ClinicalTrials.gov, last updated 2026-06-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3.4M in research payments for this study in 2025 (210 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rahul Aggarwal, M.D. Internal Medicine · San Francisco, CA
- Tanya B. Dorff, M.D. Medical Oncology · Duarte, CA
- Joseph W. Kim, MD Medical Oncology · New Haven, CT
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- Russell Z. Szmulewitz, M.D. Medical Oncology · Chicago, IL
- Manish Sharma, M.D. Medical Oncology · Grand Rapids, MI
- John D. Powderly II, M.D. Hematology & Oncology · Huntersville, NC
- Benedito A. Carneiro, MD Medical Oncology · Providence, RI
- Anthony W. Tolcher Medical Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Carolina Biooncology Institute $688,404
- Start Midwest LLC $433,772
- Rhode Island Hospital, RI $395,320
- City of Hope National Medical Ctr $394,484
- Adventhealth Orlando, FL $285,664
- Yale University $281,537
- The University of Chicago $271,192
- New Experimental Therapeutics $259,486
- Carolina Biooncology Institute PLLC $243,117
- University of California Davis Medical Center, CA $123,227
- University of Michigan Health System, MI $46,620
- $13,018
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $600
- Yale School of Medicine $600
- Next Oncology $600
- Ucm Emergency Department Outpatient Pharmacy $600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.